MedWatch

Novo Nordisk and Eli Lilly bet on combination therapies for obesity and diabetes

Combination therapies against type 2 diabetes and obesity will define the market in future. This is according to the leading actors in this field, US-based Eli Lilly and Danish Novo Nordisk.

Foto: /Ritzau Scanpix/AP/Rick Bowmer/

During the past 10-12 years, various drugs in different classes have been launched to treat the widespread disease type 2 diabetes.

One of the most promising classes is the injectable GLP-1 receptor agonists, the ingredient in leading products like Eli Lilly's Trulicity and Novo Nordisk's Victoza, which is also approved for obesity treatment under the name Saxenda.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier